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Background: The outcome of liver resection for colorectal liver metastases (CRLM) appears
to be improving despite the fact that surgery is offered to patients with more-severe disease. To
quantify this assumption and to understand its causes we analyzed a series of patients on the
basis of a standardized severity score and changes in management occurring over the years.
Methods: Patients characteristics, operative data, chemotherapies and follow-up were re-
corded. CRLM severity was quantiﬁed according to Fongs clinical risk score (CRS), modiﬁed
to take into account the presence of bilateral liver metastases. Three periods were analyzed, in
which different indications, surgical strategies and uses of chemotherapy were applied: 1984–
1992, 1993–1998, and 1999–2005.
Results: Between January 1984 and December 2005, 210 liver resections were performed in
180 patients (1984–1992, 43 patients; 1993–1998, 42 patients; 1999–2005, 95 patients). CRLM
severity increased throughout the time periods, as did the use of neoadjuvant chemotherapies,
repeat resections, and multistep procedures. While the disease-free survival did not improve
over time, the 1-, 3- and 5-year overall survival rate increased from 85%, 30%, and 23% in the
ﬁrst period, to 88%, 60%, and 34% in the second period, and to 94%, 69%, and 46% in the
third period.
Conclusions: Analysis according to the CRS showed that despite the fact that patients had
more severe disease, the overall survival improved over the years, mainly thanks to more
aggressive treatment of recurrent disease. Management of advanced CRLM should, from the
start, take into account the likelihood of secondary procedures.
Key Words: Colorectal cancer—Colorectal liver metastases—Liver surgery—Chemother-
apy—Survival.
Adenocarcinoma of the colon and rectum is a
common disease in Europe and in the United States,
with an incidence of between 15 and 40 per 100,000
people per year. Despite radical removal of their
primary tumor, 30% to 40% of the patients will
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eventually die from local or distant recurrences. Liver
metastases develop in approximately one half of the
patients,1–3 and are the commonest cause of death.
Surgical resection of colorectal liver metastases
(CRLM) is a safe and eﬀective treatment,4–8 with 5-
year survival rates ranging from 20% to 40%
depending on the pattern of the disease, on operative
techniques and on the era of the investigation. The
modern picture of the surgical management of
CRLM, however, is complex. In the past, surgery was
the only effective treatment that could be applied to a
minority of patients with a relatively favorable dis-
ease pattern or location (10% to 25%). At present,
more patients with advanced disease can undergo
operations due to improved surgical techniques and
neoadjuvant chemotherapies that can downstage
initially unresectable disease.9,10 In addition, a mul-
tidisciplinary approach has changed the management
and outcome of recurrences after liver surgery, and
patients can be offered repeat resections, percutane-
ous ablation procedures and new chemotherapy reg-
imens.10–15
The present study, based on the analysis of 210
liver resections in 180 patients during three time
periods, illustrates the results of the modern treat-
ment of CRLM, stratifying patients according to the
severity of the disease, and aims to identify the dif-
ferent factors that have changed the outcome of this
condition.
PATIENTS AND METHODS
Patient Selection
All patients who underwent a liver resection for
CRLM from January 1984 to December 2005 were
entered prospectively in a liver resection database.
The indication for surgery was a possibility to resect
all disease observed by imaging studies (R0 resec-
tion), regardless of the number of procedures needed
to achieve this goal. Patients 70 years or older were
considered as the elderly patient population. Patients
with CRLM who did not have liver resections were
excluded from the study.
Periods
Three distinct periods could be identiﬁed according
to the pattern of referrals and to diﬀerent attitudes in
the use of chemotherapy:
 1984 to 1992: upfront surgical resections in patients
with relatively favorable anatomy, disease pattern
and operative risk; occasional use of neoadjuvant
chemotherapy (12.2%); occasional use of adjuvant
chemotherapy (4.7%).
 1993 to 1998: the majority of patients received
neoadjuvant chemotherapy, based on 5-ﬂuoroura-
cil (5FU) and leucovorin (55%); more frequent use
of adjuvant chemotherapy (28.6%).
 1999 to 2005: regular use of irinotecan and
oxaliplatin, generally in a neoadjuvant setting.
Strategies used in this period included portal vein
embolization to prepare the liver for extensive
resection,16 two-step hepatectomies17,18 and a
‘‘reversed’’ approach for synchronous liver metas-
tases—with neoadjuvant chemotherapy, liver
resection and resection of the primary tumor, in
that order—as published recently.19
Chemotherapy Deﬁnitions
Chemotherapy was deﬁned as all the chemothera-
peutic cycles delivered, including chemotherapy given
after recurrence, with the exception of chemotherapy
given as radiotherapy sensitization. Neoadjuvant
chemotherapy was deﬁned as the chemotherapy
delivered before the liver resection. Adjuvant che-
motherapy was deﬁned as consolidation chemother-
apy delivered within the year following liver
resection. Chemotherapies delivered as treatment of
recurrences were not considered as adjuvant.
Data
Data included age, gender, American Society of
Anesthesiology (ASA) classiﬁcation of operative risk,
tumor-nodes-metastasis (TNM) classiﬁcation and the
site of the primary tumor, presence of extrahepatic
tumor sites, and the chemotherapy given before and/
or after surgery. Surgical details included the type of
operation, blood transfusions, histology of the re-
sected liver and tumors, resected tumor margins,
postoperative complications and outcome. When
patients had a nonresectable recurrence, palliative
treatment was under the care of the referring oncol-
ogist, and data recorded after such a recurrence
concerned the type and date of recurrence, the
radiofrequency ablation treatment, and the chemo-
therapy.
Clinical Risk Score
The patients were classiﬁed retrospectively
according to Fongs classiﬁcation20 using a clinical
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risk score (CRS), validated on large cohorts of pa-
tients in the United States and Europe.20–22 The score
is based on ﬁve clinical criteria, each one assigned one
point: positive lymph node status of the primary tu-
mor, disease-free interval from the resection of the
primary to discovery of the liver metastases of less
than 12 months, number of liver metastases greater
than one, preoperative carcinoembryonic antigen
(CEA) level greater than 200 ng/ml, and size of the
largest tumor greater than 5 cm. A CRS greater or
equal to 3 has been validated as a cutoff deﬁning
more severe disease.20 In the present investigation we
modiﬁed the CRS by adding the presence of bilateral
liver metastases as a new point (abbreviated mCRS in
this paper). Bilaterality was associated with more
widespread disease and with more complex manage-
ment (such as two-step operations and portal vein
embolization). A recent multicenter study showed
that bilaterality was an independent factor of poor
outcome in a multivariate analysis (p < 0.01).23
The purpose of Bilaterality in the mCRS was not to
use it as a new prognostic marker but to use the
mCRS as a scale of disease complexity, to compare
the management of CRLM between diﬀerent time
periods. Bilaterality was not associated with de-
creased survival in our study.
Imaging Studies
Routine imaging studies before liver resection in-
cluded an abdominal and thoracic computed
tomography (CT) scan. The use of magnetic reso-
nance imaging (MRI) increased after 1997, as well as
the positron emission tomography (PET) CT scan.
The use of intraoperative ultrasound by liver sur-
geons has been standard since 1988, and is now
considered mandatory in our center.
Surgery
During surgery, a complete exploratory laparot-
omy was performed. The liver was inspected, pal-
pated and examined by intraoperative ultrasound.
Liver resections were classiﬁed according to Couin-
aud and Bismuth, with major hepatectomies deﬁned
by the resection of at least three segments.24 Simul-
taneous colonic and liver resections were performed
in selected circumstances (right colon or <1–2 seg-
ments and left colon), but rectal resections and
complex liver resections were not performed during
the same operation. When neoadjuvant chemother-
apy was used, the resection of all CRLM was planned
based not only on the most recent CT scan or MRI
but also on the CT scan before chemotherapy was
started, to avoid leaving missing metastases behind.
Follow-Up
Follow-up was provided within a dedicated surgi-
cal oncology unit, or in collaboration with the
referring private oncologist according to the patients
preference.
Statistics
Life-table curves (global survival endpoints, death;
and tumor-free survival endpoints, deﬁnite tumor
recurrence or death) were analyzed with the Kaplan-
Meier method and distributions were compared by
the log-rank test. In case of simultaneous analysis of
more than two populations, statistical diﬀerences
were assessed by an extension of Gehans generalized
Wilcoxon test, Peto and Petos generalized Wilcoxon
test and the log-rank test algorithms, using the Stat-
istica 5.5 software (Statsoft Inc, Tulsa, OK, US).
Continuous data were analyzed by bilateral Students
t test and dichotomous data were analyzed by v2 test.
P values lower than 0.05 were considered signiﬁcant.
RESULTS
Demographics
A total of 210 liver resections were performed on
180 patients. In the ﬁrst period (1984–1992), 43 pa-
tients had 45 liver resections; in the second period
(1993–1998), 42 patients had 46 resections; and in the
third period (1999–2005), 95 patients had 119 resec-
tions. The characteristics of the patients for the three
periods are summarized in Table 1.
Postoperative Mortality
The postoperative mortality (within 60 days) did
not diﬀer during the three time periods, and involved
only one patient who died of liver failure 12 days
after a repeat hepatectomy in the third time period
(overall mortality, 0.5%).
Chemotherapy
During the ﬁrst period, chemotherapy was deliv-
ered to 36.6% of the patients, neoadjuvant chemo-
therapy was delivered to 12.2% of the patients, and
adjuvant chemotherapy was delivered to 4.7% of the
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TABLE 1. Demographic data. Patients characteristics are listed according to the three different time periods. Statistical
analysis between periods is shown for each factor
1984–1992 1993–1998 1999–2005 Statistical test p =
Patients (n) 43 42 95
Resections (n) 45 46 119
Sex female/male ratio (n) 23/20 13/29 41/54 v2 Period 1–2 0.004
Period 2–3 0.178
Period 1–3 0.260
Age: median [range] 61 [37–79] 64 [39–77] 61 [33–81] t test 1–2 0.184
2–3 0.227
1–3 0.769
ASA 1–2/3–4 ratio (n) 36/5 37/5 74/13 t test 1–2 0.871
2–3 0.405
1–3 0.840
Overall chemotherapy: yes/no ratio (n) 15/26 35/5 81/8 v2 1–2 2.4 x 10)6
2–3 0.54
1–3 5.3 · 10)11
Neoadjuvant chemotherapy: yes/no ratio (n) 5/36 22/18 74/12 v2 1–2 0.00004
2–3 0.0002
1–3 1.01 · 10)15
Adjuvant chemotherapy: yes/no ratio (n) 2/41 12/30 23/72 v2 1–2 0.003
2–3 0.589
1–3 0.006
Metastases : multiple/solitary ratio (n) 22/21 19/23 59/35 v2 1–2 0.058
2–3 0.056
1–3 0.200
Primary lymph nodes status: positive/
negative ratio (n)
28/15 23/18 60/30 v2 1–2 0.389
2–3 0.244
1–3 0.860
Metastases: synchronous/metachronous
ratio (n)
18/24 33/9 68/27 v2 1–2 0.0008
2–3 0.391
1–3 0.001
CEA > 200 at diagnosis: yes/no
ratio (n)
1/34 4/32 18/45 v2 1–2 0.174
2–3 0.044
1–3 0.002
Metastase size > 5cm at diagnosis:
yes/no ratio (n)
17/24 13/27 25/47 v2 1–2 0.404
2–3 0.812
1–3 0.476
CRS: 0–1–2/3–4–5 ratio (n) 23/9 25/9 30/29 v2 1–2 0.880
2–3 0.032
1–3 0.052
mCRS: 0–1–2/3–4–5–6 ratio (n) 16/8 21/13 24/34 v2 1–2 0.702
2–3 0.059
1–3 0.037
Liver metastastic involvement:
bilateral/unilateral ratio (n)
6/26 15/27 43/51 v2 1–2 0.109
2–3 0.275
1–3 0.007
Liver resection: major/minor ratio (n) 31/12 25/17 54/41 v2 1–2 0.222
2–3 0.770
1–3 0.088
Microscopic margins of resected
metastases: positive/negative ratio (n)
6/29 8/34 8/73 v2 1–2 0.829
2–3 0.152
1–3 0.270
Hospital stay after resection (days):
median [range]
17 [6–64] 13 [4–59] 11 [4–41] t test 1–2 0.037
2–3 0.126
1–3 0.00002
Follow-up time between resection and last
control/death (years): median [range]
1.46
[0.03–15.96]
3.26
[0.36–10.91]
1.69
[0.01–6.32]
See survival
curves
ASA, American Society of Anesthesiology classiﬁcation of operative risk; CEA, carcinoembryonic antigen; CRS, clinical risk score; mCRS,
modiﬁed clinical risk score.
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patients (Table 1). No patient during this period
underwent a two-stage procedure or a portal vein
embolization.
During the second period, chemotherapy was
delivered to 88% of the patients, mostly 5FU-leuco-
vorin. In contrast to the ﬁrst time period, the majority
of patients received neoadjuvant chemotherapy
(55%), and the proportion of patients who received
adjuvant chemotherapy signiﬁcantly increased (Ta-
ble 1). A two-step procedure was performed in one
case and portal embolization was never used.
During the third time period, when compared to
the second, the number of patients who received
neoadjuvant chemotherapy increased signiﬁcantly
(Table 1), with 5FU, oxaliplatine, and irinotecan
(CPT11) as the main drugs. The proportion of pa-
tients who received chemotherapy, and in particular
adjuvant chemotherapy, remained similar to those in
the second time period (Table 1). Patients with bilo-
bar CRLM had, when appropriate, a two-stage pro-
cedure (n = 13) or a portal vein embolization prior
to surgery (n = 11).
During the last time period, seven patients under-
went radiofrequecy ablation treatment for recur-
rence.
Survival
For the 180 patients operated between 1984 and
2005, overall 1-, 2-, 3- and 5-year survival rates were
95%, 74%, 58% and 40%, respectively, from the time
of the liver metastases diagnosis, and 90%, 66%, 55%
and 36% from the time of the liver resection.
The delay between the diagnosis of the metastases
and liver resection increased signiﬁcantly from the
ﬁrst to the third time period. This reﬂected the use of
longer neoadjuvant treatments, as well as procedures
to prepare for R0 resection such as portal emboliza-
tion, or unilateral resection of the metastases and
contralateral portal vein ligation (Fig. 1).
The overall survival at 1, 2, 3, and 5 years increased
signiﬁcantly from the ﬁrst to the third time periods
(ﬁrst period, 83%, 46%, 29% and 22%; second period,
88%, 68%, 60%, and 34%; third period, 94%, 77%,
69% and 46%) (Fig. 2). The 5-year survival rate from
CRLM diagnosis also increased from the ﬁrst (23%),
to the second (39%), and to the third time period
(50%).
The disease-free survival did not increase signiﬁ-
cantly from 1984 to 2005 (Fig. 3a) while the differ-
ence between the overall and the disease-free survival
rates increased from the ﬁrst to the third time periods
(Figs. 3b, 3c and 3d).
CRS and Modiﬁed CRS
Patients with a CRS below 3 had a signiﬁcantly
better survival than patients with a CRS equal or
greater than 3 (cumulative proportion surviving at 5
years after R0 resection with low vs. high CRS, 44%
vs. 21%, p = 0.031). Considering a cut-off of 3, more
patients had a high CRS in the third time period
compared to the two previous periods (Table 1), and
the difference was signiﬁcant for the second and third
time periods (p = 0.032).
Of the ﬁve items included in the CRS, only simul-
taneity and CEA signiﬁcantly increased from the ﬁrst
FIG. 1. The time (in days) elapsed between the diagnosis of liver
metastases and the R0 liver resection is shown for each period. The
delay is statistically longer from the ﬁrst to the last time period
(bilateral Students t test).
FIG. 2. Overall survival since R0 resection in each period is shown
as separated Kaplan–Meier curves. Overall survival significantly
increased from the first to the last time period. Numbers in
brackets correspond to the patients who underwent operations in
each period.
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to the last time periods (Table 1). Multiplicity of
metastases increased between periods, although fell
short of statistical signiﬁcance (p = 0.58 between the
ﬁrst and second time periods,and 0.056 between the
second and third time periods), and the proportion of
patients presenting with bilateral metastases in-
creased from the ﬁrst to the third time period (19%
vs. 36% vs. 46%) (Table 1).
Although bilateralism of metastases was not sta-
tistically discriminant for better or worse survival per
se (p = 0.26), it allowed a ﬁner analysis of outcome
when added to the CRS (cumulative proportion
surviving at 5 years after R0 resection with low vs.
high mCRS, 56% vs. 14%, p = 0.017).
When survival curves were compared for patients
with low mCRS in the diﬀerent time periods, there
was a signiﬁcant improvement in overall survival
(OS) (Fig. 4a) and disease-free survival (DFS)
(Fig. 4b) between the ﬁrst period and the last two
periods (OS: ﬁrst time period at 1, 3 and 5 years, 86%,
46% and 36%; second and third time periods at 1, 3
and 5 years, 95%, 71% and 63%; p = 0.035; DFS:
ﬁrst time period at 1, 3 and 5 years, 50%, 16% and
0%; second and third time periods at 1, 3 and 5 years,
58%, 45% and 38%; p = 0.046).
For patients with a high mCRS, there was a sig-
niﬁcant improvement in OS during the last time
period as compared to the ﬁrst two periods (OS: ﬁrst
and second time periods at 1, 3 and 5 years, 90%, 43%
and 5.3%; third period at 1, 3 and 5 years, 90%, 60%
and 24%; p = 0.047) (Fig. 4c), but no improvement
in DFS (Fig. 4d).
Young and Elderly Patients
The proportion of elderly patients who had oper-
ations increased between time periods (ﬁrst period,
ﬁve elderly patients out of 43 patients; second period,
eight of 42, third period, 20 of 95), although the in-
crease was not statistically signiﬁcant.
The DFS remained similar for young and elderly
patients between the three periods (p = 0.51 for
young patients, p = 0.1 for elderly patients). In
contrast, the overall survival increased between time
FIG. 3. Disease-free survival in each period and comparison with
overall survival. Disease-free survival since R0 resection did not
increase with time, as shown by (A) the Kaplan–Meier curve for
each period. Although the difference between overall survival (OS)
and disease-free survival (DFS) was significant for each period
analyzed, the difference increased from (B) the first to (C) the
second and to (D) the third period, reflecting a better survival after
recurrence.
b
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periods for young patients (p = 0.0004), but not for
older patients (p = 0.48) (Fig. 5a and 5b).
Among the 33 elderly patients, only one had a
second resection for recurrence compared to 16
among the 147 young patients (p = not signiﬁcant
(NS)). No elderly patients had a two-step resection,
three had a preoperative portal embolization (vs. 12
young patients, p = NS).
The proportion of elderly patients who had neo-
adjuvant chemotherapy was similar to the younger
population (48% vs. 63%, p = NS), but only 65% of
elderly patients received chemotherapy postopera-
tively, versus 84% of young patients (p = 0.013).
DISCUSSION
This study shows that: (1) the severity of CRLM in
patients presenting to surgeons, represented by the
CRS, increased over the three time periods, and (2)
that despite the increasing CRS, the long-term sur-
vival improved over these same periods.
Two reasons explain why the severity of the met-
astatic disease increased over time. The ﬁrst is that
more eﬀective chemotherapy regimens (with response
rates as low as 10–20% in the first time period and in
the range of 60–70% in the most recent time period)
have been applied to the neoadjuvant setting,25 ren-
dering resectable those patients with previously un-
resectable disease.10,11 These patients had by
deﬁnition a very advanced disease. The second reason
is that liver surgery has developed techniques that
speciﬁcally address the limitations of multiplicity, of a
small residual liver and of proximity to major ana-
tomical structures, without compromising safety.9
Although the increasing severity of patients oper-
ated for CRLM is taken for granted in most spe-
cialized centers, this is the ﬁrst investigation that
presents this point as a measurable factor. While the
CRS was devised as a prognostic score, it oﬀers a
standardized tool and allows appreciation of the
severity of the disease, and the diﬃculty of the sur-
gery that is needed to resect it,19 especially with the
FIG. 4. Survival of patients presenting with low and high mCRS,
according to periods. Periods were grouped in order to analyze
survival between (A and B) the ﬁrst time period versus the second
and third time periods, and between (C and D) the ﬁrst two time
periods versus the third period. With such cut-offs, overall survival
(OS) and disease-free survival (DFS) since R0 were analyzed for
patients presenting low and high mCRS. For patients with low
mCRS, (A) OS as well as (B) DFS improved signiﬁcantly from the
ﬁrst period to the last two periods. In contrast, for patients with a
high mCRS, (C) OS, but not (D) DFS improved signiﬁcantly.
b
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additional factoring of bilateral metastases. The
stratiﬁcation of patients using the mCRS allowed us
to compare the three time periods and the results of
similar patients during the periods. We suggest that
the mCRS, the CRS or a similar tool should be used
when reporting the results of surgery for CRLM, to
offer a common basis for comparison between dif-
ferent treatments and/or different centers.
The stratiﬁcation of patients in the diﬀerent risk
categories and during diﬀerent periods allowed us to
identify the factors responsible for the improved
survival rate over time. The selection of patients with
a more favorable risk proﬁle did not play a role, as
the proportion of patients with advanced disease in-
creased in the most recent periods. Similarly, factors
that are commonly cited, such as lower mortality and
better resection techniques, were irrelevant or minor
in the present series: the only postoperative death
occurred in the most recent period. Surgical progress
was indeed important in expanding the limits for safe
resection of advanced disease, and in operating safely
on patients with chemotherapy-induced liver chan-
ges,26,27 which may impact on postoperative mortal-
ity,28 but these aspects are difﬁcult to quantify.
The more frequent use and the increased eﬀec-
tiveness of chemotherapy appeared to be the two
major factors responsible for the increased overall
survival rate, aﬀecting the outcome at diﬀerent levels.
From a theoretical point of view, chemotherapy may:
1. Have a systemic effect on undetected extrahepatic
metastases. Hematogenous malignant cells have
been detected in advanced colorectal cancer, and
the manipulation of CRLM may be associated
with a high risk of intraoperative tumor cell
dissemination.29–31
2. Prolong survival after relapse, when the disease is
no longer resectable.32
Both these mechanisms have probably played a
role in our patients, as shown by the reduced inci-
dence of recurrences in patients with a low CRS in the
most recent periods.
Another relevant factor, however, emerges from a
more detailed analysis of the survival patterns of
patients with a higher CRS in the most recent period.
The improvement in survival concerned overall rather
than disease-free survival, showing that the gain was
due to a better management of recurrences with re-
peat resections, radiofrequency thermal ablations and
new chemotherapy regimens.33 The corollary of this
ﬁnding is that while disease-free survival was similar
in young and elderly patients in the most recent time
period, survival after recurrence was longer in
younger patients (patients for whom the overall
management can be more aggressive compared to
older patients), suggesting a more active treatment of
recurrences.3,34
Some practical implications can be extracted from
our study. The ﬁrst one concerns reporting. Stratiﬁ-
cation according to the CRS (especially mCRS,
which takes bilateralism into account) is useful to
compare diﬀerent series and to identify the determi-
nants that inﬂuence outcome, which would be
otherwise masked by the inevitable heterogeneity of
the CRLM population.
The second implication is that as more patients
with a high CRS present to a surgical team, the
likelihood of recurrences has to be integrated into the
management program. Since recurrences can be
managed aggressively, they have to be taken into
account at the initial hepatectomy. Therefore, it
FIG. 5. Overall survival in each period for young and elderly pa-
tients. Overall survival since R0 resection of (A) young and (B)
elderly patients are shown as separate Kaplan-Meier curves cor-
responding to the different periods. Young patients are deﬁned by
< 70 years old.
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seems reasonable to perform conservative radical
resections as opposed to large hepatectomies in pa-
tients with severe disease at presentation, as further
surgery is likely. In CRLM, several studies showed
the feasibility of limited resections with safety mar-
gins of less than 10 mm without compromising the
long-term survival.35–37 A surgical approach that fa-
vors conservative R0 resection, without undue sacri-
ﬁce of vascular structures or of liver parenchyma is
therefore appropriate for most complex cases. Neo-
adjuvant chemotherapy of high efﬁcacy may play a
crucial role in this respect with maximum downsizing
of the lesions.
CONCLUSIONS
In conclusion, thanks to the classiﬁcation accord-
ing to a standardized severity score, we show in this
study that the outcome of patients with CRLM has
markedly improved over the last decade. Progress in
both surgical techniques and in systemic therapies has
contributed to these better results, and patients with
more advanced disease can now be treated with a
curative intent. Management of recurrences is the
new challenge in advanced CRLM and requires a
combination of chemotherapy and strategies to
economize liver parenchyma that allow for further
surgery if necessary.
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